# A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

> **NCT03011892** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 307 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Ruxolitinib 0.15% Cream QD
- **DRUG:** Ruxolitinib 0.5% Cream QD
- **DRUG:** Ruxolitinib 1.5% Cream QD
- **DRUG:** Ruxolitinib 1.5% Cream BID
- **DRUG:** Triamcinolone 0.1% Cream BID
- **DRUG:** Vehicle Cream BID

## Key facts

- **NCT ID:** NCT03011892
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-09
- **Primary completion:** 2018-01-10
- **Final completion:** 2018-03-12
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2021-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03011892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03011892, "A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03011892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*